Trevi Therapeutics Inc (NASDAQ:TRVI)

2.48
Delayed Data
As of Jan 27
 0.00 / 0.00%
Today’s Change
0.46
Today|||52-Week Range
4.68
+28.50%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$146.8M

Company Description

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Contact Information

Trevi Therapeutics, Inc.
195 Church Street
New Haven Connecticut 06510
P:(203) 304-2499
Investor Relations:
(203) 903-9627

Employees

Shareholders

Mutual fund holders5.39%
Other institutional41.14%
Individual stakeholders20.70%

Top Executives

Jennifer L. GoodPresident, Chief Executive Officer & Director
Lisa DelfiniChief Financial Officer
Thomas R. SciasciaChief Science Officer
Danine SummersVice President-Medical Affairs
David J. ClarkChief Medical Officer